Site-directed mutagenesis employs synthetic oligonucleotides as primers to deliberately replace specific bases in DNA. Smith’s 1978 report allowed researchers to explore how single amino-acid changes affect protein function. The method revolutionized studies of enzyme active sites, receptor-ligand interactions, and antibody affinity engineering. Originally, mutant strands were enriched using M13 phage vectors, but modern PCR-based “QuikChange” protocols now dominate. Site-directed mutagenesis opened the door to protein engineering and molecular evolution, directly enabling industrial enzymes and biopharmaceuticals.

Smith’s oligonucleotide-directed mutagenesis introduced the desired mutation within a synthetic primer, extended it on a single-stranded DNA template, and selectively recovered the mutant strand. Using phosphorylated primers, DNA ligase and the Klenow fragment of DNA polymerase I, he achieved high mutation efficiency. PCR-based variants (megaprimer, QuikChange) later simplified the workflow, enabling cloning-free and multi-site modifications. Resulting mutant proteins are evaluated by activity assays, X-ray crystallography, NMR, and molecular dynamics simulations. Coupling with DNA shuffling or error-prone PCR accelerates directed-evolution experiments, optimizing enzyme performance and antibody affinity.

Oligonucleotide-directed mutagenesis embeds intentional mismatches in synthetic primers and employs mismatch repair or selectable markers for mutant screening. In M13 systems, preferential replication of the mutant strand leveraged gpII nick sites and nick translation. PCR-derived approaches suffer from primer self-annealing background, mitigated by phosphorothioate primers and high-fidelity polymerases. Hybridization with CRISPR-Cas–mediated nicking now enables single-stranded oligodeoxynucleotide (ssODN) HDR with high efficiency in mammalian cells. Deep sequencing quantifies off-target and indel profiles, guiding algorithmic primer design and library screening strategies.